Meda AB (publ), Interim Report January – September 2008

• The Group’s net sales reached SEK 7,515 million (5,821), a 29% increase compared to the previous year.

• EBITDA rose by 32% to SEK 2,616 million (1,981), [1] thus yielding a 34.8% margin (34.0).

• Operating profit rose to SEK 1,826 million (1,323).

• Profit after tax climbed to SEK 808 million (749).

• Profit per share reached SEK 3.12 (3.20). Profit per share, excluding non-recurring profit impact rose to SEK 3.12 (3.00). [2]

• Full-year forecast for 2008, excl. acquired operations
(i.e. excl. effects from acquisitions of Valent’s operations, Roche’s product portfolio, and any restructuring costs)

"The Meda Group estimates it will reach sales of about SEK 10,000 million for 2008. EBITDA for 2008 is estimated to reach SEK 3,300 million, including significant pre-launch expenses in the US for Astepro and Onsolis amounting to about SEK 100 million during Q4.”

Valeant’s acquired operations and Roche’s product portfolio that will be entirely consolidated during Q4 are projected to supply the Meda Group with about SEK 1,600 million in sales annually, which is not included in the forecast.

For more information, contact:

Anders Larnholt, Investor Relations
Telephone: +46-8-630 19 62, +46-709-458 878

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.


Documents & Links